Purdue Pharma denies EY conflicts of interest, fraudulent transfers
Purdue Pharma entered bankruptcy in September facing thousands of lawsuits over the opioid crisis. (Credit: iStock.com/BackyardProduction)
Bankrupt US OxyContin maker Purdue Pharma has denied claims its plan to hire EY would create a conflict of interest, as it fights fraudulent transfer claims raised in the US Supreme Court.
To read more
Subscribe to Global Restructuring Review
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Restructuring Review experts.
Subscribe now